ALZ-NET: examining novel approved treatments in the real-world

A call to review the CMS national coverage determination of anti-amyloid antibodies

Potential clinical meaningfulness of donanemab data

Topline donanemab results: most positive Phase III data to date

Approval of aducanumab for Alzheimer’s disease

Medical management issues in dementia: recommendations

EAN guidance on managing patients with dementia

Dementia, stress and the molecular age of the brain

The benefits of GWAS in understanding Alzheimer’s disease

Therapeutic development in Alzheimer’s disease and the lack of funding

Cross neurodegenerative disease genetic analysis: similarities and differences

Identifying new therapeutic targets for neurodegenerative diseases

The future of Alzheimer’s disease: aducanumab

Dementia and stress: the challenges

Hopeful developments for Alzheimer’s Disease

Defining Alzheimer’s disease: clinical or biological